Calpain Inhibitors, a Treatment for Alzheimer's Disease

Principal Investigator
Fortunato Battaglia, MD
Research Foundation for Mental Hygiene
New York, NY, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2003 - March 31, 2005
Grant ID
A2003230
Summary
Today’s treatments for Alzheimer’s disease (AD) are simply treat the symptoms without arresting the disease. The next generation of drugs may delay the onset or slow the progression by acting on the cause(s) of the illness. Evidence suggests that the impairment of synaptic communication between neurons may significantly contribute to the symptoms and progressive deterioration associated with AD. Possible candidates as causes of AD are a particular type of proteins called calpains. These proteins have shown the ability to destroy most of the cellular protein pool at abnormally high calcium levels and to regulate the production of beta-amyloid precursor protein, one of the neuropathologic hallmarks of the disease. In so doing, they may be responsible for mediating the early molecular events of the illness. Dr. Battaglia is investigating how a treatment with calpain inhibitors may restore normal communication between synaptic transmission and thereby slow the progression of the disease. Calpain inhibitors have already been used in the therapy of various other diseases. Analyzing the effects of calpain inhibitors in animal models of Alzheimer’s might help to identify a new treatment for AD.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD